COMP <GO>
CDNA vs MRK // GROSS PROFIT MARGIN
CareDx Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: CDNA 4
— MRK 9
▲ GROSS PROFIT MARGIN LEADER: MRK
LAST: $87.41 (+22.22%) • MKT CAP: $3.70B
gross-margins
41.00%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
gross-margins
74.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CDNA VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CDNA | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 41.00% | 74.80% | -33.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -8.20% | 20.70% | -28.90 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.67% | 3.42% | -2.75 | MRK | /fcf-yield <GO> |
| Operating Margin | -8.10% | 34.30% | -42.40 | MRK | /operating-margins <GO> |
| Net Profit Margin | -5.60% | 28.10% | -33.70 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 13.80% | 1.30% | +12.50 | CDNA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 19.22 | 5.19 | +14.03 | CDNA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 6.60% | +0.50 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 81.9 | 56.9 | +25.04 | CDNA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.06 | 0.92 | +0.14 | CDNA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.0x | 18.4x | +2.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.70B | $361.02B | -$357.32B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CDNA REV | MRK REV | CDNA GROSS % | MRK GROSS % | CDNA FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $379.8M | $65.01B | 44.0% | 74.8% | $24.9M | $12.36B |
| FY 2024 | $333.8M | $64.17B | 44.0% | 76.3% | $23.0M | $18.10B |
| FY 2023 | $280.3M | $60.12B | 44.0% | 44.0% | -$31.0M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CDNA // BETA 1.06
MRK // BETA 0.92